All Releases
 |
VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Jun 11, 2009
|
10.6 KB |
|
| |
SAN FRANCISCO, June 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced today that an end of Phase 2a meeting for the Company's lead drug, VIA-2291 (atreleuton), was re...
|
|
VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
Jun 4, 2009
|
10.5 KB |
|
| |
SAN FRANCISCO, June 4, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced today that preclinical data related to diacylglycerol acyl transferase - 1 (DGAT1) inhibitors wil...
|
|
VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients
May 14, 2009
|
11.8 KB |
|
| |
SAN FRANCISCO, May 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed enrollment in a Phase 2 clinical trial of its lead drug, VIA-2291 in ...
|
|
VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
May 1, 2009
|
11.5 KB |
|
| |
WASHINGTON and SAN FRANCISCO, May 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP) today announced the results of a sub-study of patients in its acute coronary syndrome (ACS) Phase 2 trial who received serial 64 slice multidetector computed tomography (MDCT) scans before and after six months of trea...
|
|
VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
Apr 3, 2009
|
9.8 KB |
|
| |
SAN FRANCISCO, April 3, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has received a letter, dated March 31, 2009, from the staff of the NASDAQ Stock Ma...
|
|
VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
Mar 31, 2009
|
10.3 KB |
|
| |
SAN FRANCISCO, March 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that an abstract on the Company's Phase 2 clinical trial of VIA-2291 has been accepted fo...
|
|
VIA Pharmaceuticals Complies With NASDAQ Rules
Mar 27, 2009
|
9.9 KB |
|
| |
SAN FRANCISCO, March 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the independent audit rep...
|
|
VIA Pharmaceuticals Secures Financing Up to $10.0 Million
Mar 12, 2009
|
10.3 KB |
|
| |
SAN FRANCISCO, March 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced it has entered into a $10.0 million secured note purchase agreement (together with certai...
|
|
VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
Feb 25, 2009
|
9.6 KB |
|
| |
SAN FRANCISCO, Feb 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced the issuance of United States Patent No. 7,495,024 entitled "Phenylalkyl N-Hydroxyureas for...
|
|
VIA Pharmaceuticals Licenses Drug Candidates from Roche to Expand Cardiovascular Pipeline to Include Metabolic Disease
Dec 23, 2008
|
10.7 KB |
|
| |
SAN FRANCISCO, Dec 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc.
(Nasdaq: VIAP), a biotechnology company focused on the development of
compounds for the treatment of cardiovascular disease, today announced
exclusive, worldwide licensing agreements with Roche (SWX: ROG) for two sets
of compounds. The first ...
|
|
VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
Nov 9, 2008
|
17.2 KB |
|
| |
NEW ORLEANS and SAN FRANCISCO, Nov 09, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today the results of two Phase 2 studies of its lead drug, VIA-2291. In each Phase 2 study, VIA...
|
|
VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
Nov 6, 2008
|
7.1 KB |
|
| |
SAN FRANCISCO, Nov 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will hold a conference call and webcast to discuss results of the VIA-2291 Phase 2 acute coronary...
|
|
VIA Pharmaceuticals Announces Upcoming Investor Conference Presentations
Nov 4, 2008
|
6.7 KB |
|
| |
SAN FRANCISCO, Nov 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that VIA management will present at three upcoming investor conferences.
The presentation detai...
|
|
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
Sep 24, 2008
|
10.3 KB |
|
| |
SAN FRANCISCO, Sept 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed the last patient visit in its Phase 2 acute coronary syndrome (ACS) study, includi...
|
|
VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Sep 15, 2008
|
9.9 KB |
|
| |
SAN FRANCISCO, Sept 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that two abstracts on the company's Phase 2 trials of VIA-2291 in patients with acute coronary syndrome ...
|
|
VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
Sep 9, 2008
|
10.8 KB |
|
| |
SAN FRANCISCO, Sept 09, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will host a science briefing on Tuesday, September 16, 2008 at 12:00pm Eastern Time in New York ...
|
|
VIA Pharmaceuticals to Present at Merriman Curhan Ford's Investor Summit 2008
Sep 9, 2008
|
7.2 KB |
|
| |
SAN FRANCISCO, Sept 09, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that James G. Stewart, senior vice president and chief financial officer, will present a company update at Mer...
|
|
VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
Aug 12, 2008
|
7.2 KB |
|
| |
SAN FRANCISCO, Aug 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that James G. Stewart, senior vice president and chief financial officer of VIA, will present a company u...
|
|
VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
Aug 1, 2008
|
6.8 KB |
|
| |
SAN FRANCISCO, Aug 01, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that Rebecca A. Taub, MD, VIA's senior vice president of research and development, will present at the 13...
|
|
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
Jul 10, 2008
|
11.3 KB |
|
| |
SAN FRANCISCO, July 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed the last patient visit in its carotid endarterectomy (CEA) study. The excised caro...
|
|
|
